Girish Putcha
Directeur Technique/Scientifique/R&D chez Orion Genomics LLC
Profil
Girish Putcha is currently working as the Director-Laboratory Science at Palmetto GBA LLC and as the Medical Director at Orion Genomics LLC.
Previously, he worked as a Director at Phenomix Corp., Novasys Medical, Inc., and PowerVision, Inc. He also worked as a Medical Director at Aviir, Inc. and as a Director-Clinical Laboratory at TOMA Biosciences, Inc. Additionally, he worked as a Consultant at CardioDx, Inc. and Veracyte, Inc. He started his career as an Associate at Panorama Capital LLC.
Dr. Putcha holds a doctorate degree from Stanford University and Washington University School of Medicine.
He also holds an undergraduate degree from Rice University and a graduate degree from the University of London.
Postes actifs de Girish Putcha
| Sociétés | Poste | Début |
|---|---|---|
Palmetto GBA LLC
 Palmetto GBA LLC Medical/Nursing ServicesHealth Services Palmetto GBA LLC provides medical services. Its services include transaction processing, technological connectivity, professional education and training, and clinical decision management. The company was founded in July 1966 and is headquartered in Columbia, SC. | Corporate Officer/Principal | - |
Orion Genomics LLC
 Orion Genomics LLC Medical/Nursing ServicesHealth Services Orion Genomics LLC provides genomics research and clinical laboratory services to healthcare and agricultural research organizations. It develops genomic research tools and oncology diagnostic products for cancer screening and therapy selection. The company was founded by Robert A. Martienssen, W. Richard McCombie, John D. McPherson and Richard K. Wilson in 1998 and is headquartered in St. Loius, MO. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Girish Putcha
| Sociétés | Poste | Fin |
|---|---|---|
Phenomix Corp.
 Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Directeur/Membre du Conseil | 28/10/2010 |
TOMA Biosciences, Inc.
 TOMA Biosciences, Inc. Medical SpecialtiesHealth Technology TOMA Biosciences, Inc. develops and provides DNA-based cancer testing technology. The company was founded by Hanlee Ji, Lincoln Nadauld, James M. Ford, and Calvin J. Kuo in 2011 and is headquartered in Foster City, CA. | Corporate Officer/Principal | - |
Panorama Capital LLC
 Panorama Capital LLC Investment ManagersFinance Panorama Capital LLC (Panorama Capita) is a venture capital firm founded in 1995 by Chris Albinson, Rod Ferguson, Shahan Soghikian and damion wicker. The firm is headquartered in Campbell, California. | Analyste en capital-investissement | - |
| VERACYTE, INC. | Corporate Officer/Principal | - |
| CARDIODX INC | Corporate Officer/Principal | - |
Formation de Girish Putcha
| University of London | Graduate Degree |
| Rice University | Undergraduate Degree |
| Stanford University | Doctorate Degree |
| Washington University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VERACYTE, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
PowerVision, Inc.
 PowerVision, Inc. Electronic ComponentsElectronic Technology PowerVision, Inc. develops fluid-controlled intraocular lens. The firm provides FluidVision accommodating intraocular lens technology, which restores the vision of youth to middle aged or elderly individuals affected by presbyopia and cataracts regain to adjust focus for clear vision at all distances. The company was founded by Matthew A. Frinzi, Randy McDonald, and Barry Cheskin in 2002 and is headquartered in Belmont, CA. | Electronic Technology |
Novasys Medical, Inc.
 Novasys Medical, Inc. Medical/Nursing ServicesHealth Services Novasys Medical, Inc. develops therapies for women's health. The company was founded by Stuart D. Edwards and Peter S. Edelstein on June 24, 1999 and is headquartered in Newark, CA. | Health Services |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Aviir, Inc.
 Aviir, Inc. Medical/Nursing ServicesHealth Services Aviir, Inc. discovers, develops and commercializes diagnostic laboratory tests for cardiovascular diseases. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. The company was founded in 2005 and is headquartered in Irvine, CA. | Health Services |
CardioDx, Inc.
 CardioDx, Inc. Medical/Nursing ServicesHealth Services CardioDx, Inc. operates as a cardiovascular genomic diagnostics firm. It develops proprietary tests that improve treatment decisions and patient outcomes on coronary artery disease, cardiac arrhythmia, and heart failure. The company was founded by David L. Levison and Christopher R. Burrow in 2004 and is headquartered in Redwood, CA. | Health Services |
Panorama Capital LLC
Panorama Capital LLC Investment ManagersFinance Panorama Capital LLC (Panorama Capita) is a venture capital firm founded in 1995 by Chris Albinson, Rod Ferguson, Shahan Soghikian and damion wicker. The firm is headquartered in Campbell, California. | Finance |
TOMA Biosciences, Inc.
TOMA Biosciences, Inc. Medical SpecialtiesHealth Technology TOMA Biosciences, Inc. develops and provides DNA-based cancer testing technology. The company was founded by Hanlee Ji, Lincoln Nadauld, James M. Ford, and Calvin J. Kuo in 2011 and is headquartered in Foster City, CA. | Health Technology |
Palmetto GBA LLC
Palmetto GBA LLC Medical/Nursing ServicesHealth Services Palmetto GBA LLC provides medical services. Its services include transaction processing, technological connectivity, professional education and training, and clinical decision management. The company was founded in July 1966 and is headquartered in Columbia, SC. | Health Services |
Orion Genomics LLC
Orion Genomics LLC Medical/Nursing ServicesHealth Services Orion Genomics LLC provides genomics research and clinical laboratory services to healthcare and agricultural research organizations. It develops genomic research tools and oncology diagnostic products for cancer screening and therapy selection. The company was founded by Robert A. Martienssen, W. Richard McCombie, John D. McPherson and Richard K. Wilson in 1998 and is headquartered in St. Loius, MO. | Health Services |
